Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 43

Results For "support"

3178 News Found

HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology
News | February 09, 2026

HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology

HCG clinicians contributing to one of the largest bodies of oncology research from India


Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles
News | February 09, 2026

Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles

Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26


DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies
News | February 09, 2026

DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies

Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments


Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder
News | February 09, 2026

Mirum Pharmaceuticals bags Canadian nod for LIVMARLI to treat rare liver disorder

LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution


FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026
News | February 07, 2026

FUJIFILM India unveils four new imaging & healthcare IT solutions at IRIA 2026

Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy


Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease
Drug Approval | February 07, 2026

Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease

This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease


Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients
Drug Approval | February 07, 2026

Pfizer’s HYMPAVZI bags FDA priority review, targeting younger & hard-to-treat hemophilia patients

HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors


£1bn London Cancer Hub expansion wins planning approval
R&D | February 07, 2026

£1bn London Cancer Hub expansion wins planning approval

The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site


Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients
Clinical Trials | February 07, 2026

Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients

The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing